The addition of immunotherapy to platinum-based chemotherapy has led to significant health benefits in patients with nasopharyngeal cancer, but immune-related adverse events require vigilant care provided by an interprofessional, multidisciplinary care team. The principles of interprofessional collaboration and real-world strategies for implementation are outlined.
Course Credit:
0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours
Dates:
Opens: 2025-10-31
Closes: 2026-10-31
Target Audience:
This activity was developed for nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients with nasopharyngeal cancer.
This activity was self-funded by Annenberg Center for Health Sciences.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Rachel Feaster, PharmD, BCOP (Medical Writer)No significant relationships to disclose.
Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.
Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Robert Ferris, MD, PhD
Associate Senior Vice Chancellor for Cancer Research, Health Sciences
Hillman Professor of Oncology
Professor of Otolaryngology, of Immunology, and of Radiation Oncology, School of Medicine
Director, UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania -
Christopher Flores, MD
Family Medicine Physician
Eisenhower Medical Center
Rancho Mirage, California -
LaTosha Mollette, DNP
Family Nurse Practitioner
Louisiana Family Medicine Clinic
Jonesboro, Louisiana -
Michael Smith, PharmD
Clinical Pharmacist in Pain/Palliative Care
University of Michigan
Ann Arbor, Michigan
Contributing Faculty
Learning Objectives
- Describe the evolution in the treatment landscape for patients with nasopharyngeal cancer.
- Identify strategies to improve interprofessional care of patients with cancer, including nasopharyngeal cancer.
Faculty Disclosures
Robert Ferris, MD, PhD
Advisory Board: Adaptimmune, Bristol-Myers Squibb, Coherus BioSciences, Inc., CureVac, Eisai Europe Limited, Genmab, Hookipa Biotech GmbH, Instil Bio, Inc, Lifescience Dynamics Limited, MacroGenics, Inc., MeiraGTx, LLC, Merck, Merus NV, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, Rakuten Medical, Inc, Regeneron, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Vir Biotechnology, Inc
Board of Directors: CytoAgents
Consultant: Adagene Incorporated, Aduro Biotech, Inc., Bicara Therapeutics, Inc, Brooklyn ImmunoTherapeutics LLC, Catenion, EMD Serono, Everest Clinical Research Corporation, F. Hoffmann-La Roche Ltd, Federation Bio, Inc, Genocea Biosciences, Inc, Kowa Research Institute, Inc., Mirati Therapeutics, Inc, Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, PPD Development, L.P., Sanofi, Zymeworks, Inc.
Data Safety Monitoring Board: Mirror Biologics, Inc.
Research Support: Bristol-Myers Squibb, AstraZeneca/MedImmune, Novasenta, Tesaro